- Home
- ZEPP vs AARD Comparison
ZEPP vs AARD Comparison
Compare ZEPP & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZEPP | AARD |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.7M | 281.1M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZEPP | AARD |
|---|---|---|
| Price | $14.07 | $4.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $19.63 |
| AVG Volume (30 Days) | 84.0K | ★ 403.5K |
| Earning Date | 03-15-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $778.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.13 | $4.74 |
| 52 Week High | $61.50 | $17.94 |
Technical Indicators
Market Signals| Indicator | ZEPP | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 30.19 | 24.03 |
| Support Level | $2.28 | $4.74 |
| Resistance Level | $15.85 | $6.19 |
| Average True Range (ATR) | 1.61 | 0.52 |
| MACD | -0.55 | -0.03 |
| Stochastic Oscillator | 10.17 | 11.72 |
Price Performance
Historical ComparisonAbout ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.